{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:21:25Z","timestamp":1769764885048,"version":"3.49.0"},"reference-count":25,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0803-x","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T10:03:56Z","timestamp":1574330636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature"],"prefix":"10.1136","volume":"7","author":[{"given":"Marcela","family":"Carausu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Beddok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois-Cl\u00e9ment","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Ange","family":"Massiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5515-9180","authenticated-orcid":false,"given":"Luc","family":"Cabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"803_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-3-319-57901-6_14","volume-title":"Cancer neurology in clinical practice: neurological complications of Cancer and its treatment","author":"D Ricard","year":"2018","unstructured":"Ricard D, Durand T, Tauzi\u00e8de-Espariat A, Leclercq D, Psimaras D. Neurologic complications of radiation therapy. In: Schiff D, Arrillaga I, Wen PY, editors. Cancer neurology in clinical practice: neurological complications of Cancer and its treatment. Cham: Springer International Publishing; 2018. p. 241\u201373. [cited 2019 Jun 23]. Available from: \nhttps:\/\/doi.org\/10.1007\/978-3-319-57901-6_14\n\n."},{"key":"803_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0360-3016(88)90046-6","volume":"14","author":"TE Schultheiss","year":"1988","unstructured":"Schultheiss TE, Stephens LC, Maor MH. Analysis of the histopathology of radiation myelopathy. Int J Radiat Oncol Biol Phys. 1988;14:27\u201332.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"803_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1046\/j.1440-1789.2001.00408.x","volume":"21","author":"S Okada","year":"2001","unstructured":"Okada S, Okeda R. Pathology of radiation myelopathy. Neuropathology. 2001;21:247\u201365.","journal-title":"Neuropathology."},{"key":"803_CR4","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.ijrobp.2009.04.095","volume":"76","author":"JP Kirkpatrick","year":"2010","unstructured":"Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys. 2010;76:S42\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"803_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13014-015-0334-7","volume":"10","author":"V Lewitzki","year":"2015","unstructured":"Lewitzki V, Andratschke N, Kuhnt T, Hildebrandt G. Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib. Radiat Oncol. 2015;10:29.","journal-title":"Radiat Oncol"},{"issue":"3","key":"803_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s13691-019-00367-5","volume":"8","author":"Katsumaro Kubo","year":"2019","unstructured":"Kubo K, Wadasaki K, Yamane H, Doi M. Radiation myelitis after durvalumab administration following chemoradiotherapy for locally advanced non-small cell lung cancer: an illustrative case report and review of the literature. Int Canc Conf J. 2019; [cited 2019 Apr 8]; Available from: \nhttps:\/\/doi.org\/10.1007\/s13691-019-00367-5\n\n.","journal-title":"International Cancer Conference Journal"},{"key":"803_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40425-018-0361-7","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R. Radiation therapy and PD-1\/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer. 2018;6:46.","journal-title":"J Immunother Cancer"},{"key":"803_CR8","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16:e498\u2013509.","journal-title":"Lancet Oncol"},{"key":"803_CR9","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.ijrobp.2007.11.075","volume":"71","author":"TE Schultheiss","year":"2008","unstructured":"Schultheiss TE. The Radiation Dose\u2013Response of the Human Spinal Cord. Int J Radiat Oncol Biol Phys. 2008;71:1455\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"803_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0936-6555(96)80042-2","volume":"8","author":"FR Macbeth","year":"1996","unstructured":"Macbeth FR, Wheldon TE, Girling DJ, Stephens RJ, Machin D, Bleehen NM, et al. Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. The Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol). 1996;8:176\u201381.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"803_CR11","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1080\/02841860701864668","volume":"47","author":"M Adamus-G\u00f3rka","year":"2008","unstructured":"Adamus-G\u00f3rka M, Brahme A, Mavroidis P, Lind BK. Variation in radiation sensitivity and repair kinetics in different parts of the spinal cord. Acta Oncol. 2008;47:928\u201336.","journal-title":"Acta Oncol"},{"key":"803_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0360-3016(90)90126-5","volume":"19","author":"RB Marcus","year":"1990","unstructured":"Marcus RB, Million RR. The incidence of myelitis after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys. 1990;19:3\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"803_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jtho.2018.01.012","volume":"13","author":"HG Hubbeling","year":"2018","unstructured":"Hubbeling HG, Schapira EF, Horick NK, Goodwin KEH, Lin JJ, Oh KS, et al. Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung Cancer. J Thorac Oncol. 2018;13:550\u20138.","journal-title":"J Thorac Oncol"},{"key":"803_CR14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijrobp.2017.02.003","volume":"98","author":"A Bang","year":"2017","unstructured":"Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, et al. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. Int J Radiat Oncol Biol Phys. 2017;98:344\u201351.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"803_CR15","doi-asserted-by":"crossref","unstructured":"Fareed MM, Pike LRG, Bang A, Huynh MA, Taylor A, Spektor A, et al. Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy. Front Oncol. 2019:9 [cited 2019 Jul 31]. Available from: \nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6450051\/\n\n.","DOI":"10.3389\/fonc.2019.00199"},{"key":"803_CR16","doi-asserted-by":"crossref","unstructured":"Chang VA, Simpson DR, Daniels GA, Piccioni DE. Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation. J Immunother Cancer. 2018:6 [cited 2019 Apr 22] Available from: \nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6303890\/\n\n.","DOI":"10.1186\/s40425-018-0471-2"},{"key":"803_CR17","first-page":"757","volume":"37","author":"GM O\u2019Kane","year":"2014","unstructured":"O\u2019Kane GM, Lyons TG, Colleran GC, Ahmad MW, Alken S, Kavanagh EC, et al. Late-onset paraplegia after complete response to two cycles of Ipilimumab for metastatic melanoma. ORT. 2014;37:757\u201360.","journal-title":"ORT."},{"key":"803_CR18","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s10637-011-9787-1","volume":"30","author":"F Bompaire","year":"2012","unstructured":"Bompaire F, Mateus C, Taillia H, De Greslan T, Lahutte M, Sallansonnet-Froment M, et al. Severe meningo-radiculo-neuritis associated with ipilimumab. Investig New Drugs. 2012;30:2407\u201310.","journal-title":"Investig New Drugs"},{"key":"803_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.29245\/2572.942X\/2016\/4.1040","volume":"1","author":"R Conry","year":"2016","unstructured":"Conry R. Central nervous system toxicities of anti-cancer immune checkpoint blockade. J Neurol Neuromedicine. 2016;1:39\u201345.","journal-title":"J Neurol Neuromedicine"},{"key":"803_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1177\/1078155215572932","volume":"22","author":"A-O Abdallah","year":"2016","unstructured":"Abdallah A-O, Herlopian A, Ravilla R, Bansal M, Chandra-Reddy S, Mahmoud F, et al. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: a case report and review of literature. J Oncol Pharm Pract. 2016;22:537\u201342.","journal-title":"J Oncol Pharm Pract"},{"key":"803_CR21","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1634\/theoncologist.2009-0090","volume":"15","author":"HA Burris","year":"2010","unstructured":"Burris HA, Hurtig J. Radiation recall with anticancer agents. Oncologist. 2010;15:1227\u201337.","journal-title":"Oncologist."},{"key":"803_CR22","first-page":"331","volume":"5","author":"S McClelland","year":"2018","unstructured":"McClelland S, Cooper PH, Acheson AK, Ciporen JN, Jaboin JJ, Mitin T. Radiation recall myelitis following paclitaxel chemotherapy: the first reported case. J Radiosurg SBRT. 2018;5:331\u20134.","journal-title":"J Radiosurg SBRT"},{"key":"803_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/0284186X.2016.1246802","volume":"56","author":"MW Ejlsmark","year":"2017","unstructured":"Ejlsmark MW, Kristiansen C, Eriksen JG, Hansen O, Bastholt L. Recall radiation myelitis after stereotactic radiation and dabrafenib in metastatic melanoma. Acta Oncol. 2017;56:109\u201310.","journal-title":"Acta Oncol"},{"key":"803_CR24","volume-title":"Radiation recall pneumonitis in a patient treated by Nivolumab for non-small cell lung Cancer, No Relapse with Rechallenge","author":"P Thor\u00e9","year":"2018","unstructured":"Thor\u00e9 P. Radiation recall pneumonitis in a patient treated by Nivolumab for non-small cell lung Cancer, No Relapse with Rechallenge, vol. 3; 2018."},{"key":"803_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40944-019-0266-5","volume":"17","author":"M Dhanushkodi","year":"2019","unstructured":"Dhanushkodi M, Iyer P, Ananthi B, Krishnamurthy A. Nivolumab-induced radiation recall dermatitis (RRD). Indian J Gynecol Oncolog. 2019;17:21.","journal-title":"Indian J Gynecol Oncolog"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0803-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0803-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0803-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:46:00Z","timestamp":1601055960000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0803-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0803-x","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"2 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NG reports fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Roche\/Genentech, and AstraZeneca for consultancy, travel, research outside the submitted work. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}